КЛИНИЧЕСКИЙ СЛУЧАЙ ПО ПРИМЕНЕНИЮ ПРЕПАРАТА НУВИК® (СИМОКТОКОГ АЛЬФА) В ХИРУРГИИ ПРИ ГЕМОФИЛИИ А

Abstract

Hemophilic patients are at an increased risk of hemorrhagic complications during surgical interventions with 25% to 32% occurrence in the postoperative period even if the target parameters of hemostasis were achieved. A clinical case of a 15 y/o patient with a moderate form of hemophilia A who had undergone extensive surgical intervention against the background of the use of the Nuwiq® (Simoctocog alfa (coagulation factor VIII human recombinant)) drug by Octapharma AG (Lachen, Bezirks March, Kanton Schwyz, Schweiz) is presented in this Article. The introduction of the drug had provided the normal hemostasis during the surgical intervention and contributed to the rapid recovery of the patient during the postoperative period.